Highlights Bright Minds Biosciences Inc.

Equities

DRUG

CA10919W4056

Market Closed - Canadian Securities Exchange Other stock markets 11:48:37 2024-05-16 EDT			5-day change	1st Jan Change
1.43 ^CAD	0.00%		+4.38%	-32.55%

05-16	Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
03-22	Bright Minds Biosciences Inc. announced that it expects to receive $0.05416 million in funding	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-15	CI
Bright Minds Biosciences Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-12	CI
Bright Minds Biosciences Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	12-29	CI
Bright Minds Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-14	CI
Bright Minds Biosciences on "Positive" qEEG Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101	23-08-08	MT
Bright Minds Biosciences Brief: Announcing "Positive" qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101	23-08-08	MT
Bright Minds Biosciences Inc. Announces Positive qEEG (Quantitative Electroencephalogram) Data from Its First-In-Human Phase 1 Study of Lead Compound, Bmb-101	23-08-08	CI
Bright Minds Biosciences Announced "Positive" Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101	23-07-20	MT
Bright Minds Biosciences Inc. Announces Successful Completion of its Three-Part Phase 1 Study of BMB-101	23-07-20	CI
Bright Minds Biosciences Brief: Announced "Positive" Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101	23-07-20	MT
Bright Minds Biosciences Brief: Will Consolidate Its Common Shares On a 5) to 1 Basis; Co's post-Consolidation Shares Expected to Begin Trading on the CSE and The NASDAQ Capital Market on July 14, 2023	23-07-11	MT
Bright Minds Biosciences Announced Proposed Share Consolidation	23-06-22	MT
Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-15	CI
Bright Minds Biosciences Receives "Favorable" Written Opinion from International Searching Authority for BMB-202	23-04-19	MT
Bright Minds Biosciences Brief: Says Received a "Favorable" Written Opinion from International Searching Authority for BMB-202	23-04-19	MT
Bright Minds Biosciences Inc. Receives Favorable Written Opinion from the International Searching Authority for BMB-202	23-04-19	CI
Bright Minds Biosciences Provides Clinical Program Updates	23-02-27	MT
Bright Minds Biosciences Brief: Providing Clinical Program Updates and Outlines Anticipated Milestones for 2023	23-02-27	MT
Bright Minds Biosciences Inc. Provides Clinical Program Updates	23-02-27	CI
Bright Minds Biosciences Warned of Potential Nasdaq Delisting	23-02-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Bright Minds Biosciences Inc.

Equities

DRUG

CA10919W4056

Highlights

Filters